Health insurers score major win with higher 2027 Medicare Advantage rates

Medicare Advantage plans will receive an average 2.5% payment increase in 2027. The administration dropped a proposal to use more recent data in risk-adjustment calculations, a change that would have reduced payments, meaning insurers will retain billions of dollars after intense industry pushback. The decision is a clear regulatory win for insurers amid rising medical costs and ongoing concerns from auditors and watchdogs about risk-adjustment abuse.

Analysis

From a margin mechanics standpoint, modest percentage moves in government-set MA revenue translate into outsized free cash flow changes for plan operators because medical cost inflation is lumpy and much of the upside falls straight to the bottom line through lower-than-expected medical loss ratios and reduced reserve build. Expect 3-6% operating income upside sensitivity for established MA-heavy insurers on every 1-2% effective lift in revenue assumptions, with even higher leverage for smaller, MA-concentrated players that carry thinner capital buffers.

Regulatory and legal dynamics remain the dominant tail risk. The audit and clawback playbook for risk-adjustment programs is well established — civil and criminal investigations, recoveries via False Claims Act suits, and classification disputes can generate multi-year liabilities and negative market reactions. The most credible reversal scenarios are policy reversals or successful enforcement actions that reset earned revenue recognition or force retrospective repayments over 12–36 months.

On competitive positioning and capital allocation, incremental cash will likely be deployed into buybacks and M&A rather than new medical investment, preserving short-term EPS momentum but increasing concentration risk. Smaller MA players can use newly available cash to fund roll-ups or expand broker distribution, compressing standalone valuations and accelerating consolidation; conversely, provider groups and hospital systems face renewed pressure to either accept narrower network rates or negotiate value-based contracts that shift utilization risk onto them.

Key Decisions for Investors

• Long UNH (UnitedHealth) 9–12 month call spread (buy 1x Jan-2027 1, net-debit structure) sized 1–2% notional: asymmetric upside from sustained MA margin tailwinds while limiting premium decay; target 25–40% upside, stop at 12% adverse move.
• Long HUM (Humana) outright equity (accumulate over 2–4 weeks on pullbacks): higher MA mix gives clearer cash-flow gearing to favorable reimbursement regimes; size 1.5–2% position, trim into 10–15% gains for funding selective pair trades.
• Pair trade: Long ELV (Elevance Health) vs Short HCA (HCA Healthcare) — 60/40 notional split. Rationale: payor margin tailwinds vs provider throughput pressure. Time horizon 6–12 months; set stop-loss at 8% on either leg and target 20–30% relative spread tightening.
• Event hedge: Buy inexpensive out-of-the-money 12–18 month puts on smaller MA-focused names (e.g., CNC) sized to protect 1–2% portfolio exposure. These protect against DOJ/OIG enforcement headlines or rule reversals that could induce large share downdrafts.
• Catalyst monitor and liquidity trigger: If CMS issues draft rule language revisiting risk-score inputs or if a major False Claims Act settlement (> $500M) emerges, reduce gross exposure to MA-oriented insurers by 30–50% within 48 hours.